Bristol-Myers Squibb (BMY) Tops Q3 EPS by 22c, Offers Guidance
Tweet
Share
E-mail
Get Alerts BMY Hot Sheet
Price: $58.13 +4.16%
Revenue Growth %: -4.6%
Financial Fact:
Research and development: 1.14B
Today's EPS Names:
CRMT, More
Revenue Growth %: -4.6%
Financial Fact:
Research and development: 1.14B
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Bristol-Myers Squibb (NYSE: BMY) reported Q3 EPS of $2.00, $0.22 better than the analyst estimate of $1.78. Revenue for the quarter came in at $11 billion versus the consensus estimate of $10.98 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2023 EPS of $7.50-$7.65, versus the consensus of $7.36.
For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- Six Flags names Mark Pauls as chief operating officer
- Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
